Clinical trials: Advanced Esophageal Cancer
Cervical Cancer, Gastric Cancer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT03652077
- Testing
- INCAGN02390
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Esophageal Cancer
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than…
- Trial name
- NCT02133612
- Testing
- paclitaxel; cisplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Gastro-Intestinal Cancer
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of…
- Trial name
- NCT05332002
- Testing
- Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Rutgers, The State University of New Jersey
Esophageal Cancer
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous…
- Trial name
- BLESS (NCT06385730)
- Testing
- neoadjuvant anti-PD-1, neoadjuvant anti-PD-1 with LDRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma progressed following treatment with…
- Trial name
- NCT03817567
- Testing
- recombinant anti-EGFR monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Metastatic Esophageal Squamous Cell Carcinoma
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT06138028
- Testing
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao Central Hospital
Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic or unresectable cancer of the esophagus or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
- Trial name
- NCT00061958
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Esophageal Squamous Cell Carcinoma
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased the pathological complete response (pCR) rate…
- Trial name
- NCT06509568
- Testing
- Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Esophageal Cancer, Stomach Cancer
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
The survival of esophageal cancer and stomach cancer (EGC) at 5 years is less than 30%. Pravastatin is a potent inhibitor of HMG-CoA reductase inhibitor that has shown increased survival in patients with advanced hepatocellular…
- Trial name
- AGIM-1 (NCT01038154)
- Testing
- Pravastatin
- Where
- Spain
- Volunteers
- 146 people
- Sponsor
- Hospital Donostia
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
The purpose of this study is to determinate the safety profile, tolerability, pharmacokinetics, and preliminary antineoplastic activity of S095033 in combination with paclitaxel in participants with advanced or metastatic…
- Trial name
- NCT05312372
- Testing
- Combination (S095033 + paclitaxel)
- Sponsor
- Institut de Recherches Internationales Servier
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie
Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and…
- Trial name
- EDGE-Gastric (NCT05329766)
- Testing
- Domvanalimab, Quemliclustat, Zimberelimab
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 332 people
- Sponsor
- Arcus Biosciences, Inc.
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH